GlassScriptPhysician profile
Daniel C Lemkuil
NPI 1730163437
$3,001.49
in general payments reported to CMS, 2019-2025
27 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,041 · 2020: $222 · 2021: $34.47 · 2022: $152 · 2023: $317 · 2024: $110 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530 · Education: $22.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.51 |
| Education | $22.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $563.21 | 2019-2023 | Eliquis, Abilify |
| Lilly USA, LLC | $297.13 | 2019-2022 | |
| Novo Nordisk INC | $276.07 | 2019-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $268.24 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.95 | 2019-2020 | |
| Pfizer INC. | $202.20 | 2019 | |
| Allergan, INC. | $191.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $174.72 | 2019-2024 | Rexulti |
| Astellas Pharma US INC | $108.89 | 2023 | Veozah |
| Amgen INC. | $97.17 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $71.40 | 2019-2020 | |
| Dexcom, INC. | $60.85 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $49.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $46.40 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $41.62 | 2019 | |
| Glaxosmithkline, LLC. | $40.95 | 2019-2020 | |
| Shire North American Group INC | $40.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $40.25 | 2019-2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $25.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.52 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.80 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.40 | 2019 | |
| True North Surgical INC | $16.56 | 2025 | |
| Janssen Biotech, INC. | $12.68 | 2019 | |
| Neurocrine Biosciences, INC. | $12.40 | 2019 | |
| Amarin Pharma, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lemkuil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.